Twist Bioscience Corp. Hits New 52-Week High of $126.24

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 126.24 on August 13, 2026. This achievement underscores the company's remarkable performance over the past year, with a notable increase of 150.53%, significantly outpacing the S&P 500's growth of 20.6% during the same period. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Twist Bioscience has garnered attention for its innovative approaches and strategic positioning within the market. The company's market capitalization stands at USD 2,730 million, reflecting its growing influence in the sector. Despite being loss-making, the company continues to navigate its financial landscape with a debt-to-equity ratio of -0.41 and a return on equity of -16.79%. Investors may find it noteworthy that the stock's performance has seen a substantial rise from its 52-week low of USD 23.50, highlighting the volatility and potential within the biotechnology space. As Twist Bioscience continues to evolve, its recent high marks a pivotal point in its ongoing journey.